Joint Letter to FDA Regarding COVID-19 Convalescent Plasma (CCP) Emergency Use Authorization (EUA) Implementation

A joint letter from America’s Blood Centers, AABB, and the American Red Cross requesting an extension of the enforcement discretion period to ensure CCP remains readily available to patients in need.